Zayed Sustainability Prize 2023 Demonstrates Global Reach and Impact with over 4,500 Submissions
15.9.2022 03:27:00 EEST | Business Wire | Press release
Following a successful 4-month submissions phase, the Zayed Sustainability Prize, the UAE's pioneering global award for recognising excellence in sustainability, has officially closed entries for its 2023 awards cycle. Over 4,500 applications were received across the five Prize categories of Health, Food, Energy, Water and Global High Schools, from a record 152 countries, demonstrating the Prize’s growing global reach and impact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220811005418/en/
The Zayed Sustainability Prize 2023 receives more than 4,500 submissions globally (Graphic: AETOSWire)
The Zayed Sustainability Prize winners will be announced at the 2023 Zayed Sustainability Prize Awards Ceremony that will be held on January 16, 2023 as part of Abu Dhabi Sustainability Week.
The Prize witnessed a 13% increase in submissions compared to last year from small and medium-sized enterprises (SMEs), nonprofit organisations and high schools. Total submissions from SMEs increased across all categories, underscoring a rising trend that SMEs are putting sustainability at the top of their agenda.
H.E. Dr. Sultan Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology and Director General of the Prize, said: “For the last 14 years the Zayed Sustainability Prize has incentivised practical solutions to global challenges that deliver tangible impact at a community level around the world. Inspired by the commitment to sustainable development and humanitarian legacy of Sheikh Zayed bin Sultan Al Nahyan, the Prize has improved the lives of 370 million people in 151 countries to date. This year, we have seen applications from a record number of countries across every category from health, food, energy, water and global high schools. I'm excited to see what creative solutions this year’s applicants will bring to the table, particularly as the UAE prepares to host COP 28 next year.”
“Given that we want to leverage COP 28 as a platform for inclusivity and practical outcomes, I am confident that the Prize can help to deliver social and economic progress from across the private sector, small business community and an increasingly active and engaged younger generation,” he added.
This year’s submissions were more diverse than ever before, revealing climate change’s impact on every country across every continent, and reflecting a growing awareness that urgent climate action is critical to meet global net zero carbon goals by mid-century.
More submissions received this year came from developing nations in Sub-Saharan Africa, South Asia, East Asia, Latin America, the Middle East, and North Africa, which is an important indication of the growing participation of developing countries in the fight against climate change.
The top submitting countries included Kenya, India, China, Egypt, Brazil and the United States. By receiving submissions from a wide range of geographies, the Prize is better equipped to deliver on its mission of driving impactful, innovative, and inspiring sustainable and humanitarian development around the world.
The Food (1,426) and Health (946) categories attracted the greatest number of submissions, followed by Energy (736) and Water (601), while the Global High Schools category received 829 submissions.
In the Food category, which received nearly 20% increase in submissions compared to last year, many entries presented solutions aimed at achieving sustainable food production to address rising food insecurity and malnutrition in a world threatened by climate change.
In the Health category, several entries address the weaknesses of the healthcare systems exposed by the Covid-19 pandemic, and offer solutions that provide more resilient, inclusive, accessible, and sustainable healthcare services to people most in need.
In the Energy category, the Prize received numerous entries focused on improving sustainable energy access in vulnerable communities, supporting United Nations Sustainable Development Goal 7, affordable and clean energy for all, and driving the low-carbon energy transition.
Finally, in the Water category, a number of entries offered solutions aimed at addressing the clean water production, climate change, and water resource management challenges faced around the world, and particularly in developing nations.
The number of submissions received from high schools grew by 55% compared to last year, which is especially encouraging and a testament to young people’s growing awareness of the challenges and risks presented by the climate crisis and of the opportunity to lead on sustainable development. Entries in the Global High Schools category proposed waste management solutions, clean energy systems, and food systems like hydroponics and aquaponics, reflecting the students’ innovative thinking and careful consideration of projects most suited for their local communities.
Following the close of submissions, the Prize now enters the evaluation stage. All entries will now be shortlisted by an independent research and analysis consultancy. A Selection Committee comprised of globally renowned industry experts will then assess the qualified entries and shortlist the candidates. The third and final tier of the evaluation process is the Jury, which will convene in October, to unanimously elect the winners in each category.
Since its launch in 2008, the US$3 million Prize has, directly and indirectly, transformed the lives of over 370 million people around the world. Its global impact continues to grow, as it further catalyses humanitarian outreach and sustainable development. Each winner in the Health, Food, Energy, and Water categories receive US$600,000 to expand the scope and scale of their sustainability solution(s), while the Global High Schools category has six winners, representing six world regions, with each winner receiving up to US$100,000.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005418/en/
Contact information
Baha Haroun
Baha.haroun@bcw-global.com
Reem Diab
Reem.Diab@bcw-global.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
